HLA-DPB1 Antikörper (AA 30-258)

Produktnummer ABIN4886618

Produktdetails anti-HLA-DPB1 Antikörper

Target: HLA-DPB1 (Major Histocompatibility Complex, Class II, DP beta 1 (HLA-DPB1))

Bindungsspezifität: AA 30-258

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser HLA-DPB1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Verwendungszweck: Rabbit IgG polyclonal antibody for HLA class II histocompatibility antigen, DP beta 1 chain (HLA-DPB1) detection. Tested with WB in Human,Mouse,Rat.

Kreuzreaktivität (Details): No cross reactivity with other proteins.

Produktmerkmale: Rabbit IgG polyclonal antibody for HLA class II histocompatibility antigen, DP beta 1 chain (HLA-DPB1) detection. Tested with WB in Human,Mouse,Rat.
Gene Name: major histocompatibility complex, class II, DP beta 1
Protein Name: HLA class II histocompatibility antigen, DP beta 1 chain

Aufreinigung: Immunogen affinity purified.

Immunogen: E. coli-derived human HLA-DPB1 recombinant protein (Position: R30-A258).

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB: Concentration: 0.1-0.5 μg/mL, Tested Species: Human, Mouse, Rat
Notes: Tested Species: Species with positive results.
Other applications have not been tested. Optimal dilutions should be determined by end users.

Kommentare:

Antibody can be supported by chemiluminescence kit ABIN921124 in WB.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Konzentration: 500 μg/mL

Buffer: Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: At -20°C for one year. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20 °C for a longer time. Avoid repeated freezing and thawing.

Referenzen für anti-HLA-DPB1 Antikörper (ABIN4886618)

Huang, Zhu, Zhang, Zhu, Liu, Zhu, Wang, Li, Yang, Dong, Liu, Chen, Zhang, Yang, Deng, Fan, Wang, Liu, Ma, Fu, Wu: "S100+ cells: a new neuro-immune cross-talkers in lymph organs." in: Scientific reports, Vol. 3, pp. 1114, (2013) (PubMed).

Details zu HLA-DPB1

Target: HLA-DPB1 (Major Histocompatibility Complex, Class II, DP beta 1 (HLA-DPB1))

Andere Bezeichnung: HLA-DPB1 (HLA-DPB1 Produkte)

Synonyme: PATR-DPB1 antikoerper, B-LB antikoerper, B-LB2 antikoerper, B-LB21 antikoerper, BLB1 antikoerper, GSP-BLB1 antikoerper, DPB1 antikoerper, HLA-DP antikoerper, HLA-DP1B antikoerper, HLA-DPB antikoerper, major histocompatibility complex, class II, DP beta 1 antikoerper, Major histocompatibility complex class II beta chain BLB1 antikoerper, PATR-DPB1 antikoerper, BLB1 antikoerper, HLA-DPB1 antikoerper

Hintergrund: HLA class II histocompatibility antigen, DP(W2) beta chain is a protein that in humans is encoded by the HLA-DPB1 gene. HLA-DPB belongs to the HLA class II beta chain paralogues. This class II molecule is a heterodimer consisting of an alpha (DPA) and a beta chain (DPB), both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The beta chain is approximately 26-28 kDa and its gene contains 6 exons. Exon one encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, exon 4 encodes the transmembrane domain and exon 5 encodes the cytoplasmic tail. Within the DP molecule both the alpha chain and the beta chain contain the polymorphisms specifying the peptide binding specificities, resulting in up to 4 different molecules.

Synonyms: DPB1 | HLA-DP | HLA-DP1B | HLA-DPB | P04440

Gen-ID: 3115

UniProt: P04440

Pathways: T-Zell Rezeptor Signalweg, Cancer Immune Checkpoints